Sanoculis is a medical device start-up company which develops an alternative new surgical procedure for the treatment of the Glaucoma. This procedure is expected to be safe, effective and simple to perform and intends to supplement currently available surgical solutions in a multi-billion international market. Sanoculis was established in 2012, originally funded by the Alfred Mann Institute at the Technion, Israel and currently funded by a private group of investors.
Provide a safe, effective and simple way to perform procedures which may compete with currently available surgical solutions.
Become the standard procedure for treating glaucoma and coinciding glaucoma and cataract surgeries.
Comprehensive patent applications filed.
Encouraging results through over 250 ex vivo and 24 in vivo pig eyes and in four human cadaver eyes, allowing the company to move forward to clinical studies.
First in human study commenced in India on January 2015 with 19 procedures already conducted. Follow-up analysis on procedure efficacy is being conducted. additional studies in humans are planned for Israel in Q1/2016.